Diagnoses of dysplasia, based on histologic analyses, dictate management decisions for patients with Barrett’s esophagus (BE). However, there is much intra- and inter-observer variation in identification of dysplasia—particularly low-grade dysplasia (LGD). We aimed to identify a biomarker that could be used to assign patients with LGD to a low- or high-risk group.